Novel MDMA Analogue Screening Program Advanced
Filed with ASX · · 3 pages · English
● A comprehensive preliminary analysis has been completed on the first batch of compounds from Emyria’s exclusively optioned MDMA analogue library, developed at the University of Western Australia (UWA) ● Nuclear-magnetic resonance (NMR) screening and high performance liquid chromatography (HPLC) have confirmed excellent purity and long-term stability at room temperature for all compounds evaluated
Earlier from Emyria
- Emyria Expands Psychiatry Advisory for Psychedelics and MDMA
- MDMA-analogues Show Promise for Parkinsons Disease
- Emyria Engages Calvert Labs for Preclinical CBD studies
- Emyria Appoints Expert Neuropharmacologist for MDMA Program
- Emyria Executes Pure CBD Agreement with AltaSciences
Later from Emyria
- Emyria selected to join Palantirs Foundry Builders Program
- MDMA Analogue Development Milestone
- Emyria Welcomes Tattarang as Strategic Investor
- Emyria receives $1,162,000 R&D Tax Incentive Refund
- Positive initial MDMA-analogue screening results
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria